Combination treatment with PD-L1 and CTLA-4 antibodies resulted in complete control of metastatic osteosarcoma in 50% of mice and drastically improved the long-term disease-free survival to 60% compared to 0% observed in mice receiving anti-PD-L1 monotherapy. This evidence concerns the gene CD274 and osteosarcoma.